Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Lilly's fourth-quarter earnings, released before the market opened Thursday, surpassed analysts' expectations by millions.

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Lilly expects full-year earnings in the range of $22.50 to $24 per share, with revenue in the range of $58 billion to $61 billion. This story was generated by Automated Insights ( ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor ...

Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B. "While the U.S ...

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight ...

The Indianapolis, Indiana-based company is set to release its Q4 earnings on Tuesday, Feb. 4. Ahead of the event, analysts expect Eli Lilly to report a profit of $5.43 per share, up 118.1% from ...